Document Detail

Recellularization of heart valve grafts by a process of adaptive remodeling.
MedLine Citation:
PMID:  11805955     Owner:  NLM     Status:  MEDLINE    
The objective of this study was to investigate if function and durability of connective tissue grafts stems from in vivo revascularization and recellularization. Viability is important for durable valve performance, demonstrated by pulmonary autografts. A pattern of in vivo recellularization occurs in xenogeneic or allogeneic heart valves decellularized prior to implantation, dictated by the tissue matrix and functional biomechanics. Porcine or sheep heart valves were decellularized with the SynerGraft antigen reduction process (a common treatment process to remove all histologically demonstrable leaflet cells), and implanted as pulmonary (n = 11) or aortic valve (n = 9) replacements in sheep. Sheep allograft pulmonary valves (n = 4) were implanted as pulmonary valve replacements. Recellularization was evaluated histologically after 3, 4, 5, 6, and 11 months, with cell phenotypes identified using specific antibodies. SynerGraft heart valves were progressively recellularized beginning with an initial cellular infiltrate, and subsequent repopulation with mature interstitial cells. This process occurs in the conduit and then in the leaflet, and is associated with revascularization of the graft. Functional, fully developed fibrocytes, actively synthesizing type I procollagen (antibody probe) were present within 3 months. As the process matured cell density and distribution became similar to native valve leaflets with localization of smooth muscle actin positive cells at the ventricularis/spongiosa interface. After 11 months, leaflet explants had no detectable inflammatory cells, were as much as 80% repopulated, and had a distribution of smooth muscle actin positive cells similar to that of the natural leaflet. SynerGraft- treated heart valve implants are repopulated by a process typical of adaptive remodeling following implantation. This antigen reduction treatment is the first successful tissue engineering effort obtaining an implant with mature recipient cells capable of matrix protein synthesis. Normal early valve function and durability is maintained.
R C Elkins; S Goldstein; C W Hewitt; S P Walsh; P E Dawson; J D Ollerenshaw; K S Black; D R Clarke; M F O'brien
Related Documents :
24799935 - Endovascular treatment of pa pseudoaneurysm caused by swan-ganz catheter.
23378015 - Impact of novel off-pump coronary artery bypass simulator on the surgical training.
23949275 - Computational fluid dynamic analysis of intracranial aneurysmal bleb formation.
8834735 - Suture loop restriction of the medtronic hall valve: late presentation of a rare compli...
12768585 - Measuring the arterial input function with gradient echo sequences.
7736655 - Differences in endothelium-dependent relaxation in various arteries from watanabe herit...
Publication Detail:
Type:  Evaluation Studies; Journal Article    
Journal Detail:
Title:  Seminars in thoracic and cardiovascular surgery     Volume:  13     ISSN:  1043-0679     ISO Abbreviation:  Semin. Thorac. Cardiovasc. Surg.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2002-01-23     Completed Date:  2002-03-05     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  8917640     Medline TA:  Semin Thorac Cardiovasc Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  87-92     Citation Subset:  IM    
Copyright Information:
Copyright 2001 by W.B. Saunders Company
University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Collagen Type I / immunology,  metabolism
Graft Enhancement, Immunologic
Histocompatibility Antigens Class II / immunology
Models, Animal
Pulmonary Valve / cytology*,  immunology,  transplantation
Time Factors
Tissue Preservation
Transplantation, Heterologous
Transplantation, Homologous
Reg. No./Substance:
0/Collagen Type I; 0/Histocompatibility Antigens Class II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Humoral immune response to allograft valve tissue pretreated with an antigen reduction process.
Next Document:  Lack of calcification of tissue engineered heart valves in juvenile sheep.